HC Wainwright Predicts Lower Earnings for Keros Therapeutics

Keros Therapeutics, Inc. (NASDAQ:KROS) – Stock analysts at HC Wainwright dropped their Q1 2026 earnings estimates for shares of Keros Therapeutics in a note issued to investors on Thursday, March 5th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.89) for the quarter, down from their previous forecast of ($0.45). The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q2 2026 earnings at ($0.91) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.66) EPS, FY2027 earnings at ($7.14) EPS, FY2028 earnings at ($5.25) EPS and FY2029 earnings at ($3.90) EPS.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.37). The company had revenue of $0.39 million during the quarter, compared to analyst estimates of $3.66 million. Keros Therapeutics had a net margin of 35.65% and a return on equity of 14.25%. The business’s revenue was down 87.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.14) EPS.

A number of other research analysts also recently issued reports on KROS. Wells Fargo & Company dropped their price target on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, March 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Keros Therapeutics in a report on Monday, December 29th. Zacks Research lowered shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Wall Street Zen cut shares of Keros Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Bank of America increased their price target on shares of Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research note on Friday, November 28th. Five investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $21.86.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $11.35 on Monday. Keros Therapeutics has a fifty-two week low of $9.12 and a fifty-two week high of $22.55. The company has a market capitalization of $345.83 million, a P/E ratio of 6.24 and a beta of 0.87. The stock has a 50-day simple moving average of $17.22 and a 200-day simple moving average of $17.05.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd raised its stake in shares of Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after purchasing an additional 1,166 shares during the last quarter. Invesco Ltd. grew its position in Keros Therapeutics by 16.6% in the 4th quarter. Invesco Ltd. now owns 87,428 shares of the company’s stock valued at $1,780,000 after buying an additional 12,449 shares during the last quarter. Empowered Funds LLC acquired a new position in Keros Therapeutics in the 4th quarter valued at $1,223,000. XTX Topco Ltd acquired a new position in Keros Therapeutics in the 4th quarter valued at $212,000. Finally, VARCOV Co. purchased a new position in Keros Therapeutics during the 4th quarter worth $261,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.